Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer

Restricted access

Background: Mutations in the BRCA1 and BRCA2 genes predispose individuals to a significantly elevated risk for breast and ovarian cancers. Identification of these individuals allows for proper screening, management, and testing of at-risk relatives. NCCN has established clinical criteria for recommending BRCA1/2 testing. Patients and Methods: A retrospective chart review of 1,123 patients with breast cancer was performed to evaluate the positive predictive values (PPVs) of 14 individual criteria for predicting BRCA1/2 mutations. Results: Two criteria had PPVs significantly below 10%. Only 2 of 115 patients who were recommended for testing based solely on the criterion of “diagnosed with breast cancer at ≤45 years of age” had pathogenic mutations at a PPV of 1.6% (95% CI, 0.2%–6.0%). Additionally, 0 of 37 individuals who underwent testing based on the criterion, “diagnosed with breast cancer at any age with ≥2 close blood relatives with breast cancer at any age” tested positive (95% CI, 0%–9%). Overall, meeting >1 criterion has a PPV of 12%, whereas meeting only 1 criterion has a PPV of 3.2% (95% CI, 1.6%–5.7%), significantly below 10% (P<.0001) for predicting BRCA1/2 positivity. Conclusions: Patients with breast cancer meeting >1 criterion constitute a population significantly enriched for BRCA1/2 mutations, whereas those meeting only 1 criterion test positive at a rate similar to unselected patients with breast cancer. These data will inform ongoing discussions regarding how to best implement BRCA1/2 genetic testing.

Author contributions: Study design: all authors. Data acquisition: Cropper, Daniels. Data analysis: Cropper, Liu, Park. Manuscript preparation: all authors.

Correspondence: Molly Daniels, MS, CGC, The University of Texas MD Anderson Cancer Center, Unit 1362, PO Box 301439, Houston, TX 77230-1439. E-mail: msdaniel@mdanderson.org
  • 1.

    Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene 2004;23:64456470.

  • 2.

    Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 2010;12:245259.

  • 3.

    McClain MR, Palomaki GE, Nathanson KL, Haddow JE. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 2005;7:2833.

    • Search Google Scholar
    • Export Citation
  • 4.

    Frank TS, Critchfield GC. Identifying and managing hereditary risk of breast and ovarian cancer. Clin Perinatol 2001;28:395406.

  • 5.

    Maxwell KN, Domchek SM, Nathanson KL, Robson ME. Population frequency of germline BRCA1/2 mutations. J Clin Oncol 2016;34:41834185.

  • 6.

    Mersch J, Jackson MA, Park M. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015;121:269275.

  • 7.

    Antoniou A, Pharoah PD, Narod S. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:11171130.

    • Search Google Scholar
    • Export Citation
  • 8.

    Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:13291333.

  • 9.

    Ford D, Easton DF, Stratton M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676689.

    • Search Google Scholar
    • Export Citation
  • 10.

    Finch AP, Lubinski J, Moller P. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:15471553.

    • Search Google Scholar
    • Export Citation
  • 11.

    Antoniou AC, Hardy R, Walker L. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 2008;45:425431.

    • Search Google Scholar
    • Export Citation
  • 12.

    Parmigiani G, Chen S, Iversen ES Jr. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 2007;147:441450.

  • 13.

    American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 1996;14:17301736; discussion 1737–1740.

    • Search Google Scholar
    • Export Citation
  • 14.

    Robson ME, Bradbury AR, Arun B. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2015;33:36603667.

    • Search Google Scholar
    • Export Citation
  • 15.

    American College of Obstetricians and Gynecologists ACOG Committee on Practice Bulletins—Gynecology ACOG Committee on Genetics Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: hereditary breast and ovarian cancer syndrome. Obstet Gynecol 2009;113:957966.

    • Search Google Scholar
    • Export Citation
  • 16.

    BRCA testing, prophylactic mastectomy, and prophylactic oophorectomy. Aetna Web site. Available at: http://www.aetna.com/cpb/medical/data/200_299/0227.html. Accessed July 26,2016.

    • Search Google Scholar
    • Export Citation
  • 17.

    Daly MB, Pilarski R, Berry M. NCCN Clinical Practice Guidelines in Oncology: Genetics/Familial HighRisk Assessment: Breast and Ovarian. Version 2.2017. Accessed April 18, 2017. To view the most recent version of these guidelines, visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 18.

    Local Coverage Determination (LCD): MolDX: BRCA1 and BRCA2 Genetic Testing (L36163). Available at: https://med.noridianmedicare.com/documents/10546/6990983/MolDX+BRCA1+and+BRCA2+Genetic+Testing+LCD/4a56d913-9db5-4e6e-a405-9031d120434f. Accessed July 26, 2016.

    • Search Google Scholar
    • Export Citation
  • 19.

    Sanford RA, Song J, Gutierrez-Barrera AM. High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer 2015;121:34223427.

    • Search Google Scholar
    • Export Citation
  • 20.

    Malone KE, Daling JR, Doody DR. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 2006;66:82978308.

    • Search Google Scholar
    • Export Citation
  • 21.

    Kurian AW, Gong GD, John EM. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 2009;18:10841091.

    • Search Google Scholar
    • Export Citation
  • 22.

    Giardiello FM, Allen JI, Axilbund JE. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol 2014;109:11591179.

    • Search Google Scholar
    • Export Citation
  • 23.

    King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 2014;312:10911092.

  • 24.

    Yurgelun MB, Hiller E, Garber JE. Population-wide screening for germline BRCA1 and BRCA2 mutations: too much of a good thing? J Clin Oncol 2015;33:30923095.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 609 405 6
PDF Downloads 138 97 5
EPUB Downloads 0 0 0